CHAT Program for Diastolic Heart Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a program called CHAT (Conversations Helpful for Awareness of Illness Trajectory), which includes video lessons and guidance from a health coach, can aid in managing Heart Failure with Preserved Ejection Fraction (HFpEF). Researchers aim to determine if this approach is user-friendly, well-received by participants, and effective in managing the condition. Participants will either continue with their usual care or receive the CHAT intervention. Those diagnosed with HFpEF and experiencing its symptoms might be suitable for this trial. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance heart failure management.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that the CHAT intervention is safe for people with HFpEF?
Research has shown that video-based programs like the CHAT Intervention are generally safe and easy to manage. This program involves watching videos and talking with a health coach, so it carries no physical risks like those associated with medications or surgeries. Studies on similar programs have not reported any serious side effects. Participants typically find these programs helpful and easy to follow. For any concerns, discussing them with the trial team is advisable.
Why are researchers excited about this trial?
Researchers are excited about the CHAT Intervention for diastolic heart failure because it offers a fresh approach that goes beyond traditional medical treatments. Unlike standard options that typically involve medications and lifestyle changes, the CHAT Intervention uses engaging, patient-centered conversations to enhance awareness of the illness trajectory. Participants watch short videos and discuss their condition with a trained health coach, which can empower them with knowledge and potentially improve their quality of life. This innovative approach focuses on education and personalized support, offering a unique complement to existing care methods.
What evidence suggests that the CHAT intervention is effective for diastolic heart failure?
Research shows that educational programs and health coaching can assist people with heart failure. Studies have found that when patients better understand their condition, they often manage it more effectively. This understanding can lead to adherence to treatments and healthier lifestyle choices, which are crucial for managing Heart Failure with Preserved Ejection Fraction (HFpEF). The CHAT program, which includes videos and coaching, is being tested in this trial to enhance patients' understanding and support their care. Participants in the CHAT Intervention Group will receive this program, while those in the Standard of Care Group will receive usual care. Early results from similar programs suggest these methods can effectively manage heart failure symptoms.
Who Is on the Research Team?
Megan J Shen, PhD
Principal Investigator
Fred Hutchinson Cancer Center
Parag Goyal, MD, MSc
Principal Investigator
Weill Medical College of Cornell University
Are You a Good Fit for This Trial?
This trial is for individuals with Heart Failure, specifically those with a condition called HFpEF. Details on who can join or reasons for exclusion are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants in the CHAT intervention group watch 7 short videos and participate in four biweekly sessions with a health coach
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator